20-F - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K/A - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

SCHEDULE 13G/A - WORK Medical Technology Group LTD (0001929783) (Subject)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. ("Hunan Saitumofei") has entered into a one-year exclusive distribution agreement (the "Agreement") with Shanghai Benke Medical Technology Co., Ltd. ("Shanghai Benke") to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the "Analyzer") in East China throughout 2026. Th

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the "Reverse Stock Split"). The Company's Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company's Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "WOK," with a new CUSIP number G9767H125. The Reverse

Hangzhou, China, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today is pleased to announce that its subsidiary, Neologics Bioscience Inc. ("Neologics"), has entered into a key service agreement (the "Agreement") with GemPharmatech Corporation ("GemPharmatech"), a Delaware-based leading contract research organization. ​This move is not only a significant milestone in WORK Medical's global expansion strategy and business diversification initiatives, but also signals a pivotal

Hangzhou, China, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has entered into an investment agreement (the "Investment Agreement") with Neologics Bioscience Inc. ("Neologics"), a Delaware-based medical technology company specializing in research and development of medical technologies, with a focus on the integration of artificial intelligence and medicine (the "R&D"), to invest US$1 million in cash to acquire a 10% equity interest in Neologics. Pur

Hangzhou, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the "Reverse Stock Split"). The Company's Class A ordinary shares will begin trading on a post-split basis when the market opens on October 21, 2025. The Company's Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "WOK," with a new CUSIP number G9767H117. The Reverse S

Hangzhou, China, Oct. 14, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that the Company received a determination letter, dated October 9, 2025 (the "Letter"), from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company of Nasdaq's determination to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company's Class A ordinary shares had a closing bid price of $0.10 or less for ten con

Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq") granting the Company an additional 180-calendar-day period to regain compliance with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The notification follows Nasdaq's initial notice on April 7, 2025, which stated that WORK Medical's stock had failed to meet the minimum

New York, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $2.9 million registered direct offering (the "Offering") for its client WORK Medical Technology Group LTD (NASDAQ: WOK) (the "Company"), a supplier of medical devices in China. Under the terms of the securities purchase agreement, the Company has agreed to sell to several investors 38,999,334 of the Company's Class A ordinary share, par value $0.0005 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.075 per share in a regi

Hangzhou, China, Sept. 25, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ: WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has entered into an agreement with several investors for the purchase and sale of 38,999,334 of the Company's Class A ordinary share, par value $0.0005 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.075 per share in a registered direct offering (the "Offering"). The purchase price for the pre-funded warrants is identical to the purchase price